In contrast, the CD45+ CTCslow group (CD45+ CTCslow defined as CD45+ CTC counts / total CTC counts < 20% cells per 5 mL blood sample from each cancer patient, 44 patients, 30.6%) exhibited a metastatic rate of only 38.6% (Fig. 2c, d). The gene discussed is PTPRC; the disease is cancer.